Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Commanding Height (GCH) hierarchy in the cancer nucleus and cancer-free resection margins from a surgically removed prostatic adenocarcinoma of a 65y old black man

ABSTRACT: We profiled the transcriptomes of the dominan nodule (Gleason score 4+5=9) and of the cancer free resection margins of a surgically removed prostate tumor from a 65y old black man. Normalized to the median of valid spots expression data where used to determine the Gene Commanding Height (GCH) Score for every coding and non-coding transcript adequately quantified in all four cancer and four normal tissue samples. The analysis proved that cancer and normal tissue have distinct gene hiearchies. The top three genes in the cancer region were: BAIAP2L1 (BAI1-associated protein 2-like 1 ), FAM71E1 (amily with sequence similarity 71, member E1 ) and MAP6D1 (MAP6 domain containing 1 ), while the top three genes in the cancer-free region were: TOR1A (torsin family 1, member A ), MRPS12 (mitochondrial ribosomal protein S12 ) and GTF2H1 (general transcription factor IIH, polypeptide 1).

ORGANISM(S): Homo sapiens

PROVIDER: GSE133906 | GEO | 2019/07/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene Commanding Height (GCH) hierarchy in the cancer nucleus and cancer-free resection margins from a surgically removed prostatic adenocarcinoma of a 47y old white man

Project description:We profiled the transcriptomes of the cancer nucleus (Gleason score 4+5=9) and of the cancer free resection margins of a surgically removed prostate tumor from a 47y old white man. Normalized to the median of valid spots expression data where used to determine the Gene Commanding Height (GCH) Score for every coding and non-coding transcript adequately quantified in all four cancer and four normal tissue samples. The analysis proved that cancer and normal tissue have distinct gene hiearchies. The top three genes in the cancer region were: LOC145474 (uncharacterized long non-coding RNA), PRRG1 (proline rich Gla (G-carboxyglutamic acid) 1) and ASAP3 (ArfGAP with SH3 domain, ankyrin repeat and PH domain 3), while the top three genes in the cancer-free region were: SFR1 (SWI5-dependent recombination repair 1 ), EDF1 (endothelial differentiation-related factor 1) and RHOD (ras homolog family member D).

2019-07-06 | GSE133891 | GEO

Gene Commanding Height (GCH) hierarchy in the cancer nucleus and cancer-free resection margins from a surgically removed prostatic adenocarcinoma of a 47y old white man

Project description:Gene Commanding Height (GCH) hierarchy in the cancer nucleus and cancer-free resection margins from a surgically removed prostatic adenocarcinoma of a 47y old white man

| PRJNA552903 | ENA

Gene Commanding Height (GCH) hierarchy in the cancer nucleus and cancer-free resection margins from a surgically removed prostatic adenocarcinoma of a 65y old black man

Project description:Gene Commanding Height (GCH) hierarchy in the cancer nucleus and cancer-free resection margins from a surgically removed prostatic adenocarcinoma of a 65y old black man

| PRJNA552983 | ENA

Hierarchal gene master regulators of one case of papillary thyroid cancer

Project description:The incidence of thyroid cancer (TC) has doubled in recent years but the molecular mechanisms responsible for various TC forms are largely unknown. We hypothesize that, in a thyroid tumor, cancer nodules and surrounding benign tissue are governed by different gene master regulators (GMRs). GMRs are defined as coding/non-coding RNAs whose strongly protected (by the homeostatic mechanisms) abundance modulates most functional pathways by coordinating the expression of their composing genes. GMRs are the most legitimate targets for TC gene therapy. However, because of strong expression control, GMRs are not selectable among TC biomarkers whose frequent regulation in large cancer patient populations indicates low protection as for minor players. We tested the hypothesis by profiling the transcriptomes of the papillary cancer and benign tissue from a surgically removed TC. The hierarchy of the known biomarkers was established for both cancer and benign regions of the tumor based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that 1/3 of the 544 known biomarkers had higher GCH in the malignant region, 1/3 in the benign region, while the rest did not discriminate between the two, raising the question of the biomarkers’ utility.

2017-03-25 | GSE97001 | GEO

Hierarchal gene master regulators of papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:The incidence of thyroid cancer (TC) has doubled in recent years but the molecular mechanisms responsible for various TC forms are largely unknown. We hypothesize that, in a thyroid tumor, cancer nodules and surrounding benign tissue are governed by different gene master regulators (GMRs). GMRs are defined as coding/non-coding RNAs whose strongly protected (by the homeostatic mechanisms) abundance modulates most functional pathways by coordinating the expression of their composing genes. GMRs are the most legitimate targets for TC gene therapy. However, because of strong expression control, GMRs are not selectable among TC biomarkers whose frequent regulation in large cancer patient populations indicates low protection as for minor players. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy.

2017-03-25 | GSE97002 | GEO

A ROLE FOR DYSTONIA-ASSOCIATED GENES IN SPINAL GABAERGIC INTERNEURON CIRCUITRY

Project description:Spinal interneurons are critical modulators of locomotor circuit function. In the dorsal spinal cord, a set of interneurons called GABApre presynaptically inhibits proprioceptive sensory afferent terminals, thus negatively regulating sensory-motor signaling. While deficits in presynaptic inhibition have been inferred in human locomotor diseases, including dystonia, it remains unknown whether GABApre circuit components are altered in these conditions. In this study, we use developmental timing to show that GABApre neurons are a late Ptf1a-expressing subclass and localize to the intermediate spinal cord. Using a microarray screen to identify genes expressed in this intermediate population, we find the kelch-like family member Klhl14, implicated in dystonia through its direct binding with torsion-dystonia related protein Tor1a. Furthermore, in Tor1a mutant mice in which Klhl14 and Tor1a binding is disrupted (Dyt1ΔE), GABApre-sensory afferent synapse formation is impaired. Our findings suggest a potential contribution of GABApre neurons to the deficits in presynaptic inhibition observed in dystonia.

2017-06-03 | GSE99590 | GEO

Context-dependent compensation among phosphatidylserine-recognition receptors

Project description:Analysis of gene expression in RPE from Mertk KO, Mertk WT, Bai1-Tg+, and Bai1-Tg- mice. The hypothesis was that gene expression profile would differ with Mertk expression and Bai1-Tg expression.

2020-10-27 | GSE106298 | GEO

Validation of the Personalized Gene Therapy by stably transfection of UBALD1 in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:An ideal cancer gene therapy would selectively destroy the cancer cells without affecting much the healthy tissue. This would be possible if and only if the cancer and normal cells of the tumor are governed by distinct gene master regulators (GMRs). Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a GMR governs the phenotype by modulating major functional pathways through controlling the expression of the involved genes. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy. In this experiment, we determined the transcriptomic effects of the stable transfection of UBALD1 gene in the BCPAP and 8505C thyroid cancer cell lines. UBALD1 was selected because it has significantly different GCHs in the two cell lines: 10.31 in 8505C and 1.12 in BCPAP. The significantly more up- and down-regulated genes in the transfected 8505C cells than in the transfected BCPAP cells compared to their untransfected counterparts validated the theory and indicated the usefulness of our personalized gene therapy approach.

2017-04-06 | GSE97427 | GEO

Validation of the Personalized Gene Therapy by stably transfection of PANK2 in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:An ideal cancer gene therapy would selectively destroy the cancer cells without affecting much the healthy tissue. This would be possible if and only if the cancer and normal cells of the tumor are governed by distinct gene master regulators (GMRs). Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a GMR governs the phenotype by modulating major functional pathways through controlling the expression of the involved genes. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy. In this experiment, we determined the transcriptomic effects of the stable transfection of PANK2 gene In the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. PANK2 was selected because it has significantly different GCHs in the two cell lines: 44.64 in BCPAP and 3.61 in 8505C. The significantly more up- and down-regulated genes in the transfected BCPAP than in the transfected 8505C cells compared to their untransfected counterparts validated the theory and indicated the usefulness of our personalized gene therapy approach.

2017-03-25 | GSE97030 | GEO

Validation of the Personalized Gene Therapy by stably transfection of DDX19B in the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines

Project description:An ideal cancer gene therapy would selectively destroy the cancer cells without affecting much the healthy tissue. This would be possible if and only if the cancer and normal cells of the tumor are governed by distinct gene master regulators (GMRs). Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a GMR governs the phenotype by modulating major functional pathways through controlling the expression of the involved genes. We determined the GMRs of the standard papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. The hierarchy of the known biomarkers was established based on their gene commanding height (GCH), an original measure combining the expression control and coordination with expression of other genes. We found that the sets of the GMRs are largely different in the two thyroid cancer cell lines, indicatibg that each type of thyroid cancer needs a different gene-targeting therapy. In this experiment, we determined the transcriptomic effects of the stable transfection of DDX19B gene In the papillary (BCPAP) and anaplastic (8505C) thyroid cancer cell lines. DDX19B was selected because it has significantly different GCHs in the two cell lines: 1.64 in BCPAP and 6.03 in 8505C. The significantly more up- and down-regulated genes in the transfected 8505C than in the transfected BCPAP cells compared to their untransfected counterparts validated the theory and indicated the usefulness of our personalized gene therapy approach.

2017-03-25 | GSE97028 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data